GenOMICC Consortium: against COVID-19 Hub
GenOMICC Consortium (Genetics of Mortality in Clinical Care) is an open global consortium of critical care clinicians studying genetics of susecptibility to critical illness with COVID-19 and other conditions
1. GenOMICC Consortium is working in partnership with Genomics England Limited and with the NHS in the project "GenOMICC study on COVID-19 patients" to deliver whole genome sequencing of up to 20,000 people who have been severely affected by COVID-19 - requiring intensive care - and 15,000 people who had mild symptoms .
This study aims to find out whether there are genetic factors that mean that some people experience severe symptoms whilst others experience only mild symptoms.
https://genomicc.org/
https://genomicc.org/protocol/
GenOMICC (Genetics Of Mortality In Critical Care) is a, open, collaborative, global community of doctors and scientists trying to understand and treat critical illness. Our partners have been recruiting patients since 2016 to study emerging infections (SARS/MERS/Flu), sepsis, and other forms of critical illness. It is the largest study of its kind anywhere in the world.
In the UK we are working with Genomics England and the UK-wide COG viral sequencing group to understand COVID-19.
Help us get to 100,000 critical illness genomes. ### COVID-19 is a key aim of GenOMICC > Susceptibility to COVID-19 is almost certainly, in part, genetic. GenOMICC can find the genes that cause susceptibility, which may help us to prioritise treatments to respond to the global crisis. GenOMICC was designed for this crisis. Since 2016, the open, global GenOMICC collaboration has been recruit patients with emerging infections, including COVID-19. All patients with confirmed COVID-19 in critical care are eligible for GenOMICC; please recruit them as normal, following local infection control precautions. > In particular, **we aim to recruit every intubated patient with COVID-19.** If you need to prioritise, please start with the youngest. > GenOMICC is prioritised as an [NIHR Urgent Public Health Study in the UK](https://www.nihr.ac.uk/covid-19/urgent-public-health-studies-covid-19.htm)
Our genes (or DNA) determine how vulnerable we are to sepsis and other forms of critical illness. We aim to discover specific genes that control the processes that lead to life-threatening illness. If we understand these processes, we think we'll be able to design effective treatments.
To do this we need to get a single DNA sample from lots of criticaly-ill patients with a range of carefully-selected conditions ( see the entry criteria here). The more patients, the better.
The GenOMICC study is supported by Sepsis Research (FEAT), the Intensive Care Society, the Wellcome Trust, and the Medical Research Council.
2.
GenOMICC also contributes to the international project 'The COVID-19 Host Genetics'.
Study design: Primary analysis is critically ill (intubated) cases vs population controls
Research category: Disease severity
Investigators: A global consortium of critical care clincians
Affiliation: University of Edinburgh
Study Type: Prospective (n=10000)
Genetic analysis: WGS; GWAS
Assays planned: Viral sequencing; Transcriptomics; Proteomics; Antibody profiling; Immune profiling
look at: https://www.covid19hg.org/partners/
1. GenOMICC Consortium is working in partnership with Genomics England Limited and with the NHS in the project "GenOMICC study on COVID-19 patients" to deliver whole genome sequencing of up to 20,000 people who have been severely affected by COVID-19 - requiring intensive care - and 15,000 people who had mild symptoms .
This study aims to find out whether there are genetic factors that mean that some people experience severe symptoms whilst others experience only mild symptoms.
https://genomicc.org/
https://genomicc.org/protocol/
GenOMICC (Genetics Of Mortality In Critical Care) is a, open, collaborative, global community of doctors and scientists trying to understand and treat critical illness. Our partners have been recruiting patients since 2016 to study emerging infections (SARS/MERS/Flu), sepsis, and other forms of critical illness. It is the largest study of its kind anywhere in the world.
In the UK we are working with Genomics England and the UK-wide COG viral sequencing group to understand COVID-19.
Help us get to 100,000 critical illness genomes. ### COVID-19 is a key aim of GenOMICC > Susceptibility to COVID-19 is almost certainly, in part, genetic. GenOMICC can find the genes that cause susceptibility, which may help us to prioritise treatments to respond to the global crisis. GenOMICC was designed for this crisis. Since 2016, the open, global GenOMICC collaboration has been recruit patients with emerging infections, including COVID-19. All patients with confirmed COVID-19 in critical care are eligible for GenOMICC; please recruit them as normal, following local infection control precautions. > In particular, **we aim to recruit every intubated patient with COVID-19.** If you need to prioritise, please start with the youngest. > GenOMICC is prioritised as an [NIHR Urgent Public Health Study in the UK](https://www.nihr.ac.uk/covid-19/urgent-public-health-studies-covid-19.htm)
Our genes (or DNA) determine how vulnerable we are to sepsis and other forms of critical illness. We aim to discover specific genes that control the processes that lead to life-threatening illness. If we understand these processes, we think we'll be able to design effective treatments.
To do this we need to get a single DNA sample from lots of criticaly-ill patients with a range of carefully-selected conditions ( see the entry criteria here). The more patients, the better.
The GenOMICC study is supported by Sepsis Research (FEAT), the Intensive Care Society, the Wellcome Trust, and the Medical Research Council.
2.
GenOMICC also contributes to the international project 'The COVID-19 Host Genetics'.
Study design: Primary analysis is critically ill (intubated) cases vs population controls
Research category: Disease severity
Investigators: A global consortium of critical care clincians
Affiliation: University of Edinburgh
Study Type: Prospective (n=10000)
Genetic analysis: WGS; GWAS
Assays planned: Viral sequencing; Transcriptomics; Proteomics; Antibody profiling; Immune profiling
look at: https://www.covid19hg.org/partners/
Connections
 Consortium.png)
Connections from
Technology:
COVID Labs/Universities
Industry:
COVID R&D
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership